Search

Author/Creator Hetherington, Seth

1. Immune responses elicited by the GEN-003 candidate HSV-2 therapeutic vaccine in a randomized controlled dose-ranging phase 1/2a trial. Issue 44 (17th October 2016)

Authors:
Flechtner, Jessica Baker; Long, Deborah; Larson, Shane; Clemens, Veronica; Baccari, Amy; Kien, Lena; Chan, Jason; Skoberne, Mojca; Brudner, Matthew; Hetherington, Seth
Journal:
Vaccine
Issue:
Volume 34:Issue 44(2016)
Page Start:
5314
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 1333Therapeutic HSV-2 vaccine (GEN003) results in durable reduction in genital lesions at 1 year. (December 2014)

Authors:
Wald, Anna; Warren, Terri; Fife, Kenneth; Tyring, Stephen; Lee, Patricia; Van Wagoner, Nicholas; Bernstein, David; Flechtner, Jessica B.; Magaret, Amalia; Morris, Amy; Hetherington, Seth
Journal:
Open forum infectious diseases
Issue:
Volume 1(2014)Supplement 1
Page Start:
S55
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized Trial. (30th January 2017)

Authors:
Bernstein, David I.; Wald, Anna; Warren, Terri; Fife, Kenneth; Tyring, Stephen; Lee, Patricia; Van Wagoner, Nick; Magaret, Amalia; Flechtner, Jessica B.; Tasker, Sybil; Chan, Jason; Morris, Amy; Hetherington, Seth
Journal:
Journal of infectious diseases
Issue:
Volume 215:Number 6(2017:Mar. 15)
Page Start:
856
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Significant Neutralizing Antibody and Cytolytic T Cell Responses to GEN-003, a Herpes Simplex Virus Immunotherapy, in a Phase 2b Study. (4th October 2017)

Authors:
McNeil, Lisa K; Baccari, Amy; Clemens, Veronica; Dominguez, David; Fenske, Tyler; Oliphant, Thomas; Perry, James; Siddall, Nicolle; Yuan, Jin; Heineman, Thomas; Hetherington, Seth; Flechtner, Jessica B
Journal:
Open forum infectious diseases
Issue:
Volume 4(2017)Supplement 1
Page Start:
S519
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Analysis of a Phase 2b Study of GEN-003, a Genital Herpes Immunotherapy, Showed Significant Reductions in Viral Shedding and Lesion Rate Vs Placebo. (4th October 2017)

Authors:
Heineman, Thomas C; Bernstein, David; Wald, Anna; Van Wagoner, Nicholas; Leone, Peter; Mayer, Kenneth; Lucksinger, Gregg; Win, Sandra; Koltun, William; Desai, Nisha; Oliphant, Thomas; Natenshon, Andrew; McNeil, Lisa K; Flechtner, Jessica B; Hetherington, Seth
Journal:
Open forum infectious diseases
Issue:
Volume 4(2017)Supplement 1
Page Start:
S59
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Sustained Lesion and Shedding Rate Reductions in Genital Herpes Patients 24 Months after Immunization with GEN-003, a Genital Herpes Immunotherapy. (4th October 2017)

Authors:
Heineman, Thomas; Mcneil, Lisa K; Oliphant, Thomas; Natenshon, Andrew; Van Wagoner, Nicholas; Flechtner, Jessica B; Hetherington, Seth
Journal:
Open forum infectious diseases
Issue:
Volume 4(2017)Supplement 1
Page Start:
S309
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Effects of Different Doses of GEN-003, a Therapeutic Vaccine for Genital Herpes Simplex Virus-2, on Viral Shedding and Lesions: Results of a Randomized Placebo-Controlled Trial. (6th July 2018)

Authors:
Van Wagoner, Nicholas; Fife, Kenneth; Leone, Peter A; Bernstein, David I; Warren, Terri; Panther, Lori; Novak, Richard M; Beigi, Richard; Kriesel, John; Tyring, Stephen; Koltun, William; Lucksinger, Gregg; Morris, Amy; Zhang, Bin; McNeil, Lisa K; Tasker, Sybil; Hetherington, Seth; Wald, Anna
Journal:
Journal of infectious diseases
Issue:
Volume 218:Number 12(2018)
Page Start:
1890
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗